Industry Insights
Stay informed to stay ahead of your competition with the latest industry trends and insights.
8 feeds
297 followers
42 articles/week
After prior trial flop, EyePoint's Duravyu bounces back with promising data in DME
Astellas doesn't see eye to eye with Europe on geographic atrophy drug Izervay
Novartis, Apellis drop dueling datasets as they race for approval in rare form of kidney disease
Fog clears to reveal Parabilis, a rebranded cancer biotech with big name backers
321 followers
50 articles/week
Novartis' $2.9B MorphoSys bet stumbles as safety signal delays filing by years
Ramping up for FDA submission, Ironwood makes further bid for $1B GI drug with subgroup data
BMS and UT San Antonio win $615k government grant to develop green pharma manufacturing processes
TCT 2024: Studies show early TAVR procedures help prevent later hospitalizations
Reporting from the frontiers of health and medicine
616 followers
78 articles/week
STAT+: Pfizer beats earnings expectations in first report after criticism by activist investor
Opinion: I’m the director of the Center for Medicare. Here’s how we executed the first round of drug price negotiation
STAT+: VCs move to launch U.S.-based companies to develop drugs developed in China
Opinion: Fecal transplants are saving lives — but are now at risk
Contains all the PharmaTimes latest World News.
322 followers
4 articles/week
Pharmaceuticals news and pharmaceutical industry analysis - FT.com
FollowThe latest drugs, health care and pharmaceutical news from the Financial Times, with expert company and industry analysis on FT.com
The latest drugs, health care and pharmaceutical news from the Financial Times, with expert company and industry analysis on FT.com
509 followers
7 articles/week
BioPharma
327 followers
25 articles/week
465 followers
2 articles/week
Events
315 followers
1 article/week
Fostering regulatory collaboration to improve access to mpox medicines
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 October 2024
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP)14-17 October 2024
Translarna: EMA re-confirms non-renewal of authorisation of Duchenne muscular dystrophy medicine
Build your own newsfeed
Ready to give it a go?
Start a 14-day trial, no credit card required.